154 related articles for article (PubMed ID: 29805684)
1. Multi-modality imaging features distinguish pancreatic carcinoma from mass-forming chronic pancreatitis of the pancreatic head.
Ruan Z; Jiao J; Min D; Qu J; Li J; Chen J; Li Q; Wang C
Oncol Lett; 2018 Jun; 15(6):9735-9744. PubMed ID: 29805684
[TBL] [Abstract][Full Text] [Related]
2. Clinical Value of Mean Platelet Volume to Platelet Ratio (MPR) in Distinguishing Mass-Forming Chronic Pancreatitis and Pancreatic Cancer.
Wang HX; Li YL; Huang JC; Ma YW; Lang R; Lyu SC
Diagnostics (Basel); 2023 Oct; 13(19):. PubMed ID: 37835869
[TBL] [Abstract][Full Text] [Related]
3. Radiomics Model Based on MR Images to Discriminate Pancreatic Ductal Adenocarcinoma and Mass-Forming Chronic Pancreatitis Lesions.
Deng Y; Ming B; Zhou T; Wu JL; Chen Y; Liu P; Zhang J; Zhang SY; Chen TW; Zhang XM
Front Oncol; 2021; 11():620981. PubMed ID: 33842325
[TBL] [Abstract][Full Text] [Related]
4. Differentiation between pancreatic carcinoma and mass-forming chronic pancreatitis: usefulness of high b value diffusion-weighted imaging.
Huang WC; Sheng J; Chen SY; Lu JP
J Dig Dis; 2011 Oct; 12(5):401-8. PubMed ID: 21955434
[TBL] [Abstract][Full Text] [Related]
5. Focal autoimmune pancreatitis: radiological characteristics help to distinguish from pancreatic cancer.
Sun GF; Zuo CJ; Shao CW; Wang JH; Zhang J
World J Gastroenterol; 2013 Jun; 19(23):3634-41. PubMed ID: 23801866
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of perfusion CT in differentiating of pancreatic ductal adenocarcinoma from mass-forming chronic pancreatitis and characterization of isoattenuating pancreatic lesions.
Aslan S; Nural MS; Camlidag I; Danaci M
Abdom Radiol (NY); 2019 Feb; 44(2):593-603. PubMed ID: 30225610
[TBL] [Abstract][Full Text] [Related]
7. Two nomograms for differentiating mass-forming chronic pancreatitis from pancreatic ductal adenocarcinoma in patients with chronic pancreatitis.
Zhang H; Meng Y; Li Q; Yu J; Liu F; Fang X; Li J; Feng X; Zhou J; Zhu M; Li N; Lu J; Shao C; Bian Y
Eur Radiol; 2022 Sep; 32(9):6336-6347. PubMed ID: 35394185
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a novel model incorporating MRI-based radiomics signature with clinical biomarkers for distinguishing pancreatic carcinoma from mass-forming chronic pancreatitis.
Liu J; Hu L; Zhou B; Wu C; Cheng Y
Transl Oncol; 2022 Apr; 18():101357. PubMed ID: 35114568
[TBL] [Abstract][Full Text] [Related]
9.
Zhang J; Jia G; Zuo C; Jia N; Wang H
BMC Cancer; 2017 Oct; 17(1):695. PubMed ID: 29061130
[TBL] [Abstract][Full Text] [Related]
10. Multiparameter diagnostic model based on
Wang G; Du L; Lu X; Chen S; Bi X; Zhang M; Luan X; Xu X; Zhang Z; Xu B; Yang J
Quant Imaging Med Surg; 2023 Sep; 13(9):5653-5663. PubMed ID: 37711769
[TBL] [Abstract][Full Text] [Related]
11. Perfusion CT - Can it resolve the pancreatic carcinoma versus mass forming chronic pancreatitis conundrum?
Yadav AK; Sharma R; Kandasamy D; Pradhan RK; Garg PK; Bhalla AS; Gamanagatti S; Srivastava DN; Sahni P; Upadhyay AD
Pancreatology; 2016; 16(6):979-987. PubMed ID: 27568845
[TBL] [Abstract][Full Text] [Related]
12. Application of 18F-FDG PET/CT combined with carbohydrate antigen 19-9 for differentiating pancreatic carcinoma from chronic mass-forming pancreatitis in Chinese elderly.
Gu X; Liu R
Clin Interv Aging; 2016; 11():1365-1370. PubMed ID: 27729779
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic Mass Characterization Using IVIM-DKI MRI and Machine Learning-Based Multi-Parametric Texture Analysis.
Malagi AV; Shivaji S; Kandasamy D; Sharma R; Garg P; Gupta SD; Gamanagatti S; Mehndiratta A
Bioengineering (Basel); 2023 Jan; 10(1):. PubMed ID: 36671655
[TBL] [Abstract][Full Text] [Related]
14. A comparative analysis of CT and MRI in differentiating pancreatic cancer from mass pancreatitis.
Jiang S; Li Y
Am J Transl Res; 2021; 13(6):6431-6438. PubMed ID: 34306383
[TBL] [Abstract][Full Text] [Related]
15. Pancreatitis and PDAC: association and differentiation.
Elsherif SB; Virarkar M; Javadi S; Ibarra-Rovira JJ; Tamm EP; Bhosale PR
Abdom Radiol (NY); 2020 May; 45(5):1324-1337. PubMed ID: 31705251
[TBL] [Abstract][Full Text] [Related]
16. Mass-forming pancreatitis versus pancreatic ductal adenocarcinoma: CT and MR imaging for differentiation.
Schima W; Böhm G; Rösch CS; Klaus A; Függer R; Kopf H
Cancer Imaging; 2020 Jul; 20(1):52. PubMed ID: 32703312
[TBL] [Abstract][Full Text] [Related]
17. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
18. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma.
Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD
J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771
[TBL] [Abstract][Full Text] [Related]
19. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
20. Optimized ROI size on ADC measurements of normal pancreas, pancreatic cancer and mass-forming chronic pancreatitis.
Ma C; Li J; Boukar MB; Yang P; Wang L; Chen L; Su L; Qu J; Chen SY; Hao Q; Lu JP
Oncotarget; 2017 Nov; 8(58):99085-99092. PubMed ID: 29228754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
